<DOC>
	<DOCNO>NCT02708992</DOCNO>
	<brief_summary>This PK study multi-dose oral cefixime regimen ( three 800 mg dos give q 8-hour schedule ) alone also co administer single 1000 mg oral dose azithromycin , within 24-hour period , order achieve total serum cefixime level mcg/mL least 20 hour . This determine tolerability regimen whether significant change cefixime PK co-administration . The primary pharmacokinetic objective : determine cefixime dose regimen three 800 mg dos give alone , q 8-hour schedule achieves total serum cefixime level exceed 2.0 mcg/mL least 20 hour ; determine cefixime dose regimen three 800 mg dos give q 8 hour schedule co-administered single 1000 mg azithromycin , achieve total serum cefixime level exceed 2.0 mcg/mL least 20 hour ; evaluate whether single 1000 mg dose azithromycin alters PK three dose regimen 800</brief_summary>
	<brief_title>Cefixime / Azithromycin pK Study</brief_title>
	<detailed_description>This PK study multi-dose oral cefixime regimen ( three 800 mg dos give q 8-hour schedule ) alone also co administer single 1000 mg oral dose azithromycin , within 24-hour period , order achieve total serum cefixime level mcg/mL least 20 hour . This determine tolerability regimen whether significant change cefixime PK co-administration . The primary pharmacokinetic objective : determine cefixime dose regimen three 800 mg dos give alone , q 8-hour schedule achieves total serum cefixime level exceed 2.0 mcg/mL least 20 hour ; determine cefixime dose regimen three 800 mg dos give q 8 hour schedule co-administered single 1000 mg azithromycin , achieve total serum cefixime level exceed 2.0 mcg/mL least 20 hour ; evaluate whether single 1000 mg dose azithromycin alters PK three dose regimen 800 mg cefixime give q 8-hour schedule . The primary safety objective assess safety tolerability treatment regimen include three dos 800 mg cefixime ; ass safety tolerability treatment regimen include three dos 800 mg cefixime co-administered single 1000 mg dose azithromycin . The study take place 10 week .</detailed_description>
	<mesh_term>Gonorrhea</mesh_term>
	<mesh_term>Cefixime</mesh_term>
	<criteria>1 . Healthy male female subject 18 45 year , inclusive 2 . Ability understand consent process procedures 3 . Informed consent obtain sign prior initiation study procedures 4 . Subjects agree available study visit 5 . Negative breathalyzer alcohol 6 . Agreement female subject reproductive potential use adequate method contraception study 30 day last study drug administration . Female subject must agree use TWO reliable method contraception receive study drug 30 day last study drug administration sexually active , include : condom , spermicidal gel , diaphragm , hormonal nonhormonal intrauterine device , surgical sterilization , oral contraceptive pill ( OCP ) , depot progesterone injection . 1 . Subjects take prescription medication regular basis ( except OCPs ) , include limited , antipsychotic , antidepressant , antiepileptic , cardiac medication , antihypertensive . 2 . Subjects take OTC drug herbal remedy regular basis , especially associate risk QT prolongation antiemetic ( ondansetron , granisetron , dolasetron , hydroxyzine ) , antihistamine ( terfenadine , astemizole , hydroxyzine , diphenhydramine ) , GI stimulant ( cisapride , domperidone , metoclopramide ) , homeopathic agent ( cinchona , licorice extract glycyrrhizin ) . 3 . Hypertension confirm systolic blood pressure &gt; 140 mmHg confirm diastolic blood pressure &gt; 90 mmHg , measure 10 15 minute rest 4 . Morbid obesity ( BMI &gt; /= 35 kg/m^2 ) 5 . Current diagnosis pulmonary disease 6 . History current diagnosis diabetes 7 . Autoimmune disorder , lupus , Wegener 's , rheumatoid arthritis 8 . History malignancy except lowgrade skin cancer , ( i.e. , basal cell carcinoma think cure ) 9 . Known diagnosis prolong QT interval , congenital long QT syndrome , bradyarrhythmias uncompensated heart failure 10 . History alcohol abuse 11 . History seizure disorder 12 . History renal disease 13 . Chronic renal , hepatic , pulmonary disease condition could interfere absorption study drug predispose adverse GI event ( e.g. , surgical resection significant proportion stomach bowel , gastric bypass , gastric banding , irritable bowel syndrome , inflammatory bowel disease ) 14 . Positive serology result HIV , hepatitis B surface antigen ( HBsAg ) , hepatitis C virus ( HCV ) antibodies 15 . Subjects take prescription drug previous 14 day within five halflives dose 16 . Ingestion OTC medication herbal supplement within seven day dose 17 . Positive urine drug screen marijuana , cocaine , amphetamine , opiate , phencyclidine , barbiturate , benzodiazepine 18 . History allergic reaction intolerance cephalosporins 19 . History allergic reaction penicillin ( stage ) 20 . History allergic reaction azithromycin , erythromycin , macrolide ketolide antibiotic 21 . History jaundice hepatic dysfunction associate prior use azithromycin 22 . Males QTcF &gt; 430ms Females QTcF &gt; 450ms ( Fridericia 's correction ) screen 23 . Positive pregnancy test ; pregnant nursing woman 24 . Screening laboratory test &gt; Grade 1 define Appendix B 25 . Any specific condition , judgment Investigator , preclude participation could affect subject safety .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 7, 2016</verification_date>
	<keyword>Azithromycin</keyword>
	<keyword>Cefixime</keyword>
	<keyword>Duration</keyword>
	<keyword>High-Dose</keyword>
	<keyword>Neisseria gonorrhoeae</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Susceptibility</keyword>
</DOC>